文献速递湿疹皮炎与荨麻疹皮肤感染

从益生元到工程菌:微生物启发的特应性皮炎治疗

From prebiotics to engineered microbes: microbe-inspired treatments for atopic dermatitis.
PubMed 文献 · Br J Dermatol · 2026-01-01

本综述探讨靶向皮肤微生物组治疗特应性皮炎(AD)的策略,包括微生物群移植、益生元、益生菌和后生元,并提出利用合成生物学工程化皮肤微生物作为下一代活体生物治疗产品,以按需感知皮肤信号并释放治疗。

要点

  • AD患者皮损中金黄色葡萄球菌定植率超过90%,驱动屏障破坏和免疫刺激。
  • 抗生素可能破坏共生微生物群,需谨慎用于无明确感染的AD患者。
  • 工程化活体生物治疗产品可感知免疫信号并按需释放治疗,是未来方向。

核心结论

  • 靶向皮肤微生物组的治疗策略(微生物群移植、益生元、益生菌、后生元及工程化活体生物治疗产品)有望改善AD的感染和炎症控制。

研究设计与样本

  • 综述类文章,检索范围未在摘要中明确报告。

主要发现

  • AD皮损中金黄色葡萄球菌定植率超过90%,与疾病严重度相关。
  • 抗生素治疗可能破坏维持皮肤和肠道健康的共生微生物群。
  • 工程化细菌可感知皮肤免疫信号和环境因子,按需产生治疗分子。

临床怎么用

  • 对无明确皮肤感染的AD患者,应避免常规使用抗生素以保护共生微生物群。
  • 微生物组靶向治疗(益生元、益生菌、后生元、微生物群移植)可作为AD的辅助或未来治疗选择。
  • 工程化活体生物治疗产品代表下一代AD治疗方向,尚需临床验证。

局限性

  • 摘要未报告综述的检索策略、纳入研究数量及证据等级。
  • 工程化细菌疗法的安全性和有效性尚未在临床研究中确立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atopic dermatitis (AD) is a common chronic inflammatory skin disease with diverse clinical and histological features. While primarily immune-mediated, genetic studies have also highlighted the role of epithelium-expressed gene abnormalities (e.g. FLG mutations) as a key factor. Approaches to treating AD are multifaceted, involving barrier restoration, local anti-inflammatory treatment and, if needed, systemic immunosuppressive therapy. Genetic variations in the stratum corneum and the immune system are linked to an imbalance between the host and its microbiota, known as dysbiosis. An impaired skin barrier and immune responses can alter the microbial composition, while the skin microbiota itself can influence skin immunity and barrier formation. A hallmark of AD is increased bacterial colonization with Staphylococcus aureus, which is found on lesional skin in > 90% of patients with AD. It contributes to disease severity by driving further breakdown of the skin barrier and immune stimulation. The most common treatments for S. aureus infections in AD are topical or systemic antibiotics. While these treatments are typically reserved for active infections, they are sometimes prescribed to patients with AD without a clear skin infection. These treatments can disrupt commensal skin and gut microbiota, which play a critical role in maintaining skin and gut health. In this review we describe various treatments that target the skin microbiome to reduce infection and inflammation in AD, including transplantation of microbiota, and the use of prebiotics, probiotics and postbiotics. In addition, we provide a perspective to engineer and harness bacteria of the skin microbiome as next-generation probiotics, also known as engineered live biotherapeutic products, using synthetic biology to create strains that can sense skin signals, such as immune signals, and environmental factors, and produce therapeutic treatments for AD on demand. Atopic dermatitis (also known as eczema) is a common long-term skin condition. It causes dry, itchy and inflamed skin. The condition affects up to 2 in 10 children and 1 in 10 adults in Europe and the USA. It is caused by a combination of an irregular immune system and faults in the outer layers of the skin. These layers act as a barrier to protect against irritants and infection. People with the condition often have an imbalance in the natural microbes of their skin. Natural microbes include bacteria, fungi and viruses. Together they are called the ‘skin microbiome’. Staphylococcus aureus are harmful bacteria. They are found in large numbers on the skin of the majority of people with eczema. They can worsen the symptoms of the condition. Although antibiotics are used to kill harmful bacteria, they can also kill helpful bacteria. Imbalances in certain fungi and viruses are also associated with eczema. In this review by authors from the Netherlands, Spain and the UK, we look at new eczema treatments that might help the skin microbiome. We discuss prebiotics (nutrients that support good bacteria), probiotics (helpful live bacteria) and postbiotics (helpful products made by bacteria). We also discuss the transplantation of some microbes from a healthy person to someone with eczema to improve their skin health. Finally, we talk about designing bacteria that can detect inflammation and release treatment only when it is needed. This could provide better treatments with fewer side effects for people with eczema. Our review shows how microbial therapies may help improve eczema care in the future.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. van Hout NE, Nevot G, Jansen PAM, et al. From prebiotics to engineered microbes: microbe-inspired treatments for atopic dermatitis. Br J Dermatol. 2026. PMID: 41231731. doi:10.1093/bjd/ljaf451

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。